Our Expert Faculty member, Dr Gil Y Melmed (Cedars-Sinai Medical Center, Los Angeles, CA, US), spoke with touchIMMUNOLOGY around the rationale for targeting IL-23 in the treatment of Crohn’s disease and the clinical development of risankizumab.
Questions
- What are the limitations of current biologic drugs in the treatment of patients with Crohn’s disease? (0:10)
- What is the rationale for targeting IL-23 in Crohn’s disease? (1:03)
- Could you give us a brief overview of the clinical development of risankizumab? (2:55)
Disclosures: Gil Y Melmed has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
